MedTrace Logo

Peripheral Blood CyTOF Immune Model for Cervical Lesion Detection in HPV16/18+ Women

NCT07606677 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1465

Last updated 2026-05-26

No results posted yet for this study

Summary

This prospective, multicenter cohort study will recruit eligible HPV16/18-positive women from three tertiary hospitals in China. Peripheral blood samples and clinical data (cytology, HPV genotyping, colposcopy-directed biopsy) will be collected, followed by standardized mass cytometry (CyTOF) to develop and evaluate an immune model across cervical lesion grades.

Conditions

  • CIN 2/3
  • Cervical Cancer (Early Detection)

Sponsors & Collaborators

  • Jiaxing Maternity and Child Health Care Hospital

    collaborator OTHER

  • Ningbo Women & Children's Hospital

    collaborator OTHER

  • Zhejiang PuLuoTing Health Technology Co., Ltd.

    collaborator UNKNOWN

  • Women's Hospital School Of Medicine Zhejiang University

    lead OTHER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2027-03-31
Completion
2028-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07606677 on ClinicalTrials.gov